CyCAR标准与RECIST标准在一线应用贝伐珠单抗治疗晚期非鳞非小细胞肺癌疗效评价中的比较  

Comparison of CyCAR standard and RECIST standard in the evaluation of efficacy of bevacizumab in the first-line treatment of advanced non squamous NSCLC

作　　者：刘阳阳 Liu Yangyang(Department of Oncology,Xintai People′s Hospital,Shandong 271200,China)

机构地区：[1]山东省新泰市人民医院肿瘤科,271200

出　　处：《山西医药杂志》2021年第20期2870-2873,共4页Shanxi Medical Journal

摘　　要：目的探讨实体瘤疗效评价标准(RECIST)标准和循环肿瘤细胞学疗效评估标准(CyCAR)在以贝伐珠单抗联合化疗方案治疗晚期非鳞非小细胞肺癌(NSCLC)患者疗效评价中的一致性。方法回顾性分析46例接受贝伐珠单抗联合化疗方案一线治疗晚期非鳞NSCLC患者临床资料,研究2种评价标准在治疗2个周期后、治疗4个周期后对晚期非鳞NSCLC患者疗效评价中的一致性,并分析治疗前后循环肿瘤细胞(CTC)计数与疗效、无进展生存时间(PFS)及总生存时间(OS)的关系。结果CTC阳性率与肿瘤转移程度、肿瘤大小具有相关性(P<0.05);在治疗2个周期、4个周期后,基于RECIST标准,应答率分别为78%和72%,基于CyCAR标准,应答率分别为67%和65%,2种疗效评价差异无统计学意义(P>0.05);治疗后CTC计数变化与PFS、OS差异有统计学意义(P<0.05)。结论在以贝伐珠单抗联合化疗方案治疗晚期非鳞NSCLC患者疗效评价中,CyCAR标准与RECIST标准存在一致性,CyCAR标准可作为疗效评价的补充方法。Objective To investigate the consistency of RECIST standard and CyCAR standard in the evaluation of the efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non squamous non-small-cell lung cancer(NSCLC).Methods The clinical data of 46 patients with advanced non squamous NSCLC treated with bevacizumab combined with chemotherapy were analyzed retrospectively.The consistency of the two evaluation criteria(RECIST standard and CyCAR standard)in the evaluation of the efficacy of patients with advanced non squamous NSCLC after 2 cycles′and 4 cycles′treatment was studied,and the relationship between circulating tumor cells(CTC)count and efficacy,progression free survival time(PFS)and overall survival time(OS)before and after treatment was analyzed.Results The positive rate of CTC was correlated with the degree of tumor metastasis and tumor size(P<0.05).After 2 and 4 cycles′treatment,the response rates were 78%and 72%based on RECIST standard,and 67%and 65%based on CyCAR standard,respectively.There was no significant difference between the two efficacy evaluations(P>0.05).There was significant difference between CTC count,PFS and OS after treatment(P<0.05).Conclusion In the evaluation of the efficacy of bevacizumab combined with chemotherapy in the treatment of advanced non squamous NSCLC,the CyCAR standard is consistent with the RECIST standard,and the CyCAR standard can be used as a supplementary method for the efficacy evaluation.

关 键 词：癌 非小细胞肺 参考标准 治疗结果 贝伐珠单抗 

分 类 号：R734.2[医药卫生—肿瘤]